BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Target Lowered at Morgan Stanley

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective cut by investment analysts at Morgan Stanley from $122.00 to $119.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley‘s target price would suggest a potential upside of 116.79% from the stock’s previous close.

Several other brokerages also recently issued reports on BMRN. Oppenheimer reduced their price objective on BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating for the company in a research note on Tuesday. UBS Group began coverage on BioMarin Pharmaceutical in a report on Thursday, October 15th. They set a “buy” rating and a $88.00 price target for the company. BMO Capital Markets reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Citigroup increased their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, William Blair raised shares of BioMarin Pharmaceutical to a “hold” rating in a research report on Wednesday, September 23rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.96.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN traded down $2.55 during mid-day trading on Tuesday, reaching $54.89. 1,587,979 shares of the company traded hands, compared to its average volume of 2,110,677. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The firm has a market cap of $10.63 billion, a PE ratio of 148.55, a price-to-earnings-growth ratio of 0.61 and a beta of 0.22. The stock has a fifty day simple moving average of $60.43 and a 200-day simple moving average of $58.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.31. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the firm earned $0.12 EPS. The business’s revenue for the quarter was up 32.0% on a year-over-year basis. Equities research analysts anticipate that BioMarin Pharmaceutical will post 2.59 EPS for the current fiscal year.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds have recently modified their holdings of the company. Primecap Management Co. CA bought a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $811,962,000. Caisse de depot et placement du Quebec acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at $70,749,000. Bank of New York Mellon Corp bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth $66,107,000. Edmond DE Rothschild Holding S.A. bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth $39,312,000. Finally, Palo Alto Investors LP acquired a new position in BioMarin Pharmaceutical during the 2nd quarter worth about $39,068,500. Institutional investors own 98.71% of the company’s stock.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with expectations. Adjusted EPS was $0.23, well above the consensus estimate for a loss of roughly $0.08–$0.09. Growth was led by a 44% increase in metabolic-condition revenue and a 12% rise in skeletal-condition revenue. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry disease asset to its clinical portfolio and reported a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, supporting BioMarin’s longer-term growth story.
• Positive Sentiment: Options activity was notably bullish, with traders purchasing 3,961 call options—about 228% above typical call volume—suggesting increased speculative interest in a potential rebound.
• Neutral Sentiment: Analyst opinion remains mixed. Citi reiterated a Buy rating, while Royal Bank of Canada maintained a Sector Perform rating, indicating that near-term execution concerns are balanced against BioMarin’s pipeline potential.
• Negative Sentiment: BioMarin lowered its 2026 adjusted EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and issued revenue guidance of $3.8 billion–$3.9 billion versus the $3.9 billion consensus. Management cited order-timing uncertainty and charges related to two acquired in-process research programs. BioMarin Q3 2026 Results and Guidance
• Negative Sentiment: Royal Bank of Canada lowered its BMRN price target from $62 to $60 while retaining its Sector Perform rating, reinforcing investor concerns about limited near-term upside.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.